Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Oct. 1 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the 9th Annual BIO Investor Forum, which is being held in San Francisco from October 5-6 at the Palace Hotel. Mr. Andrews will provide an update on the Company's drug development activities and plans. Cipher's presentation will take place on Wednesday, October 6, 2010 at 1:30 pm (PDT) in the Twin Peaks North.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (FDA approval in May 2010) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.